Business · 1 sources covering this

94% Intraday Surge: How FDA Rethink Led To Capricor Shares Record Sky-High Rally

Capricor Therapeutics shares surged 94% intraday after the FDA indicated it was willing to review additional data for deramiocel, its experimental Duchenne muscular dystrophy treatment.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·3h ago
94% Intraday Surge: How FDA Rethink Led To Capricor Shares Record Sky-High Rally
Capricor Therapeutics shares surged 94% intraday after the FDA indicated it was willing to review additional data for deramiocel, its experimental Duchenne muscular dystrophy treatment.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/80f22bed034d84ee91e1507aa7c4447d75a1d46b"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="94% Intraday Surge: How FDA Rethink Led To Capricor Shares Record Sky-High Rally"></iframe>

94% Intraday Surge: How FDA Rethink Led To Capricor Shares Record Sky-High Rally

How 1 sources are covering this

94% Intraday Surge: How FDA Rethink Led To Capricor Shares Record Sky-High Rally

More from Business

Spider-Man Beyond the Spider-Verse trailer leaks online; writer Chris Miller reacts to unfinished footage

SC slaps fine on RIL over NTPC gas supply suit

Maharashtra FDA suspends 14 licences linked to Blinkit, Zepto, Instamart

Thermo Fisher finds India the perfect lab

Reader

Trust & legal

Across the network